AWM
ALXN

Avior Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Avior Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19
Closed -$3K – 1226
2021
Q2 		$3K Hold
19
– – ﹤0.01% 882
2021
Q1 		$2K Hold
19
– – ﹤0.01% 928
2020
Q4 		$2K Hold
19
– – ﹤0.01% 898
2020
Q3 		$2K Hold
19
– – ﹤0.01% 841
2020
Q2 		$2K Buy
19
+10
+111% +$1.06K ﹤0.01% 816
2020
Q1 		$0 Sell
9
-48
-84% -$4.71K ﹤0.01% 927
2019
Q4 		$6K Buy
57
+48
+533% +$5.13K ﹤0.01% 649
2019
Q3 		$0 Buy
+9
New +$1.01K ﹤0.01% 900
2018
Q2 		– Sell
-7
Closed -$1K – 868
2018
Q1 		$1K Hold
7
– – ﹤0.01% 772
2017
Q4 		$1K Buy
+7
New +$852 ﹤0.01% 776

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Avior Wealth Management's ALXN Position: Q3 2021 in Review

Avior Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 19 shares — an estimated $3K sold.

Avior Wealth Management first reported a position in ALXN in Q4 2017 and held it in 10 quarters. The position peaked at $6K in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Avior Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Avior Wealth Management sold 19 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3K.
  • Avior Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 10 quarters.
  • Avior Wealth Management's Alexion Pharmaceuticals position peaked at $6K in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Avior Wealth Management's 13F filing for Q3 2021, filed 2 Nov 2021.